

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No: D-2885

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application

Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 CFR 1.53(b) is a new utility patent application for an invention entitled:

LEUCINE-BASED MOTIF AND CLOSTRIDIAL NEUROTOXINS

and invented by:

STEWART ET AL

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

Enclosed are Application Elements:

- ☒ Filing Fee
- ☒ Specification having page(s) and including the following:
- ☒ Title of the Invention
 - ☒ Background of the Invention
 - ☒ Brief Summary of the Invention
 - ☒ Detailed Description
 - ☒ Claim(s) as Classified Below
 - ☒ Abstract of the Disclosure
 - ☒ Sequence Listing
- ☐ Sheets of Drawings(s) (37 CFR 113) ☐ Formal ☐ Informal
- ☒ Oath or Declaration ☒ Executed ☐ Unexecuted
☐ Copy from prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- ☒ Power of Attorney ☒ Executed ☐ Unexecuted
☐ Copy from prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- ☐ Incorporation By Reference — The entire disclosure of the prior application from which a copy of the oath or declaration is supplied under the above entry, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
- ☐ Computer Program in Microfiche (Appendix)

Accompanying Application Parts

- ☒ Assignment Papers (cover sheets & documents(s))
☐ The prior application is assigned of record to
☐ Copy from prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
- ☐ English Translation Document (if applicable)

- [] Information Disclosure Statement/PTO-1449 [] Copies of _ IDS Cited Reference(s)
- [] Preliminary Amendment
- [X] Acknowledgment postcard
- [] Verified Statement(s) to Establish Small Entity Status Under 37 CFR 1.9 and 1.27
- [] Copy from prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- [X] Certificate of Mailing by Express Mail
- [] Certified Copy of Priority Document(s) (if foreign priority is claimed)
- [] Copy of Request for Extension of Time (1 month) in application
- [X] Diskette with Sequence Listing included.


Fee Calculation and Transmittal

* The filing fee is calculated on the basis of the claims existing in the prior application as amended by the accompanying preliminary amendment noted above.

CLAIMS AS FILED					
For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	43	- 20 =	23	X \$18.00	\$414.00
Independent Claims	5	- 3 =	2	X \$78.00	\$156.00
Multiple Dependent Claims (check if applicable) []					\$ 0.00
BASIC FEE					\$ 690.00
OTHER FEE (specify purpose)					\$ 0.00
SMALL ENTITY STATUS (Applicant has small entity status under 37 CFR 1.9 and 1.27)					--
TOTAL FILING FEE					\$1260.00

- [] A check in the amount of \$ __ to cover the filing fee and the assignment fee is enclosed.
- [x] The Commissioner is hereby authorized to charge and/or credit Deposit Account Number 01-0885 as described below.
- [x] Charge the amount of \$1260.00 as filing fee and assignment recordation fee.
- [x] Credit any overpayment.
- [x] Charge any additional filing fees required under 37 CFR 1.16 and 1.17.

Respectfully Submitted,



FRANK L. UXA
Attorney for Applicants
Reg. No: 25,612

4 VENTURE, SUITE 300
IRVINE, CA 92618
phone: 949-450-1750
fax: 949-450-1764

[illegible]

In the application of:

Group Art Unit: N/A

Examiner: N/A

For: LEUCINE-BASED MOTIF AND
CLOSTRIDIAL NEUROTOXINS

Express Mail Mailing Label No. EL562948685US

Date of Deposit: JULY 21, 2000

I hereby certify that the following documents as identified below are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231:

1. Application Trans. Ltr. + 2 copies;
2. Application and Declaration;
3. Sequence Listing;
4. Recordation Sheet and Assignment; and
5. Diskette with Sequence Listing included.

The above-identified 5 documents are enclosed herewith.

Respectfully submitted,

Janet E. McGhee
Office of Frank J. Uxa
Attorney for Applicant
Reg. No. 25,612
4 Venture, Suite 300
Irvine, CA 92618
(949) 450-1750
Facsimile (949) 450-1764

07-24-00

A
Box SEQ

D-2885

THE ENCLOSED PATENT APPLICATION OF STEWARD ET AL IS BEING FILED IN ACCORDANCE WITH SECTION 37 CFR 1.10 BY EXPRESS MAIL AND SHOULD BE ACCORDED A FILING DATE OF:

JULY 21, 2000

SEE THE EXPRESS MAIL CERTIFICATE ATTACHED TO THE APPLICATION.

001220-01000000